Most Read Articles
3 days ago
Higher concentrations of infliximab postinduction appear to result in early and long-term favourable therapeutic outcomes in patients with fistulizing Crohn’s disease (CD), a study has found.

Vonoprazan: A new era in the treatment of acid-related diseases

26 Nov 2019
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
3 days ago
Higher concentrations of infliximab postinduction appear to result in early and long-term favourable therapeutic outcomes in patients with fistulizing Crohn’s disease (CD), a study has found.